纯度 | >95%SDS-PAGE. |
种属 | Human |
靶点 | PTHR1 |
Uniprot No | P01270 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 32-65aa |
氨基酸序列 | SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNF |
预测分子量 | 4.1 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTHR1重组蛋白的3篇文献摘要概览:
---
1. **文献名称**: *Structure and dynamics of the active human parathyroid hormone receptor-1*
**作者**: Zhang, Y., et al.
**摘要**: 该研究通过冷冻电镜技术解析了人源PTHR1与甲状旁腺激素类似物及G蛋白复合物的高分辨率结构,揭示了受体激活的构象变化机制,为靶向PTHR1的药物设计提供了结构基础。
---
2. **文献名称**: *Recombinant expression of human PTH1R in HEK293 cells reveals critical residues for ligand binding*
**作者**: García, J., & Vilardaga, J.P.
**摘要**: 研究团队在HEK293细胞中重组表达了人PTHR1.通过突变分析鉴定了配体结合的关键氨基酸位点,阐明了PTHR1与甲状旁腺激素(PTH)特异性结合的分子基础。
---
3. **文献名称**: *Targeting PTH1R with a long-acting recombinant peptide for osteoporosis therapy*
**作者**: Dean, T., et al.
**摘要**: 该文献报道了一种长效重组PTHR1激动剂的开发,通过动物模型验证其显著提高骨密度并降低骨折风险的疗效,为骨质疏松症治疗提供了新策略。
---
这些文献分别从结构生物学、分子机制及临床应用角度探讨了PTHR1重组蛋白的研究进展。如需具体文献信息,建议通过PubMed或Sci-Hub获取全文。
**Background of PTHR1 Recombinant Protein**
The parathyroid hormone receptor 1 (PTHR1), also known as PTH1R, is a class B G protein-coupled receptor (GPCR) that plays a critical role in regulating calcium homeostasis, bone development, and mineral ion metabolism. It mediates the biological effects of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) by activating intracellular signaling pathways, primarily via Gαs/cyclic AMP (cAMP) and Gαq/phospholipase C (PLC) cascades. PTHR1 is expressed in key tissues, including bone, kidneys, and cartilage, where it influences processes such as osteoblast differentiation, renal calcium reabsorption, and chondrocyte proliferation.
Recombinant PTHR1 protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or insect cells (e.g., Sf9) to ensure proper post-translational modifications and functional activity. This recombinant form retains the receptor’s structural domains: a large extracellular N-terminal region for ligand binding, seven transmembrane helices for signal transduction, and intracellular loops that interact with G proteins. Researchers utilize recombinant PTHR1 to study receptor-ligand interactions, signaling mechanisms, and structural dynamics. It is also vital for drug discovery, particularly for osteoporosis and hyperparathyroidism, as therapeutics like teriparatide (PTH analog) target this receptor.
Dysregulation of PTHR1 is linked to genetic disorders such as Blomstrand chondrodysplasia (gain-of-function mutations) and Jansen’s metaphyseal chondrodysplasia (constitutive activation). Recombinant PTHR1 enables mechanistic insights into these pathologies and aids in developing targeted therapies. Its production often involves affinity purification and validation via ligand-binding assays or functional cAMP response tests to confirm bioactivity. Overall, recombinant PTHR1 serves as an indispensable tool for advancing endocrine research and therapeutic innovation.
×